Alex Dean

Concurrent Treatment With OX40 Agonist Antibody and PD-1 Blockade

Discussion created by Alex Dean on Apr 25, 2019

Although the potential for immunotherapy to improve outcomes for patients with cancer, particularly through a combination of agents targeting immune inhibitory pathways, is becoming increasingly evident, how to optimally combine the many new immunotherapy agents being developed remains a major question in cancer research. Now, two laboratory studies investigating the potential therapeutic and immune effects of the concurrent administration of the T-cell–stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti–programmed cell death protein 1 (PD-1) antibody has found that the simultaneous addition of anti–PD-1 to anti-OX40 negated the antitumor effects of OX40 antibody and resulted in poor treatment outcomes in mice.